

RESEARCH ARTICLE

Open Access

# Single transcription factor efficiently leads human induced pluripotent stem cells to functional microglia



Iki Sonn<sup>1,2</sup>, Fumiko Honda-Ozaki<sup>3,4</sup>, Sho Yoshimatsu<sup>1,2</sup>, Satoru Morimoto<sup>1</sup>, Hirotaka Watanabe<sup>1</sup> and Hideyuki Okano<sup>1\*</sup>

## Abstract

**Background:** Microglia are innate immune cells that are the only residential macrophages in the central nervous system. They play vital physiological roles in the adult brain and during development. Microglia are particularly in the spotlight because many genetic risk factors recently identified for neurodegenerative diseases are largely expressed in microglia. Rare polymorphisms in these risk alleles lead to abnormal activity of microglia under traumatic or disease conditions.

**Methods:** In the present study, to investigate the multifaceted functions of human microglia, we established a novel robust protocol to generate microglia from human induced pluripotent stem cells (hiPSCs) using a combination of cytokines and small chemicals essential for microglia ontogeny. Moreover, we highly enhanced the microglial differentiation efficiency by forcing the expression of PU.1, a crucial transcription factor for microglial development, during posterior mesoderm differentiation.

**Results:** By our novel method, we demonstrated the generation of a greater number of hiPSC-derived microglia (hiMGLs, approximately 120-folds) than the prior methods (at most 40-folds). Over 90% of the hiMGLs expressed microglia-specific markers, such as CX3CR1 and IBA-1. Whole-transcriptome analysis revealed that these hiMGLs are similar to human primary microglia but differ from monocytes/macrophages. Furthermore, the specific physiological functions of microglia were confirmed through indices of lipopolysaccharide responsiveness, phagocytotic ability, and inflammasome formation. By co-culturing these hiMGLs with mouse primary neurons, we demonstrated that hiMGLs can regulate the activity and maturation of neurons.

**Conclusions:** In this study, our new simple, rapid, and highly efficient method for generating microglia from hiPSCs will prove useful for future investigations on microglia in both physiological and disease conditions, as well as for drug discovery.

**Keywords:** Human pluripotent stem cells, Microglia, *SP1*, PU.1

\* Correspondence: [hidokano@a2.keio.jp](mailto:hidokano@a2.keio.jp)

<sup>1</sup>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan

Full list of author information is available at the end of the article



© The Author(s). 2022 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## Background

Microglia, the unique immune cell type in the brain parenchyma, account for 5–15% of total cells in the central nervous system (CNS) and play critical roles in adult brain homeostasis but also in neural circuit formation during brain development [1]. In the brain, microglia ramified processes reaching up to 100  $\mu\text{m}$ , continuously sense the alteration of their surrounding environment [2, 3]. During development, microglia enter the CNS during neurogenesis. At the prenatal stage, microglia are known to induce neuronal cell death, promote neuronal facilitation, and limit axon outgrowth, while they promote synapse maturation and remodel neural networks after birth [4]. Depletion of microglia during development is reported to disrupt the development of functional neurons, through the reduction of spine size and excitatory synaptic inputs [5]. Furthermore, several studies have demonstrated that besides their action on neurons, microglia also contribute to the differentiation of glial cells (oligodendrocytes and astrocytes) by secreting proinflammatory cytokines [6, 7]. In the adult brain, microglia also have a pivotal role in pathogen defense and clearance of cellular debris. In addition, microglia are also important in regulating the survival and differentiation of oligodendrocyte progenitor cells (OPCs) [8], thereby supporting adult neurogenesis in neurogenic areas and neuronal activity [9]. Finally, microglia are known to eliminate presumably weak synapses during sleep. These findings support the idea that microglia have versatile physiological functions in the adult brain [10].

Microglia has recently drawn an increasing interest because of their recently recognized implication in several neurological diseases. A number of genes specifically expressed in microglia has been identified as causative factors of several brain disorders and neurodegenerative diseases, especially Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) [11]. Therefore, it is urgent to understand the cellular biology of microglia under physiological and disease conditions. Considering species differences and a limited accessibility to human specimens, there is a thirsty need to explore a new resource of human microglia [12]. As human induced pluripotent stem cells (hiPSCs) have opened the possibility to develop new methods for studying human neural cells in multiple contexts, several protocols for deriving microglia from hiPSCs have been published thus far [13–17]. All of them are basically established on cytokine combinations requiring an extended duration of differentiation, followed by a purification (cell sorting) of the microglial progenitor cells generated. Therefore, more efficient and cost-effective protocols for generating human microglia remain to be unearthed. In contrast to other ectoderm-derived neural cell types, microglia are derived from myeloid progenitor cells in the yolk sac,

which appear in the extra-embryonic mesoderm [18–20]. Myeloid cells leave the blood island in the yolk sac and then enter the embryonic brain at the onset of blood circulation and colonize the neuroepithelium before blood-brain barrier formation.

Here, we show that a large number of human microglia-like cells (hiMGLs) can be derived from hiPSCs by a novel method, using overexpression of PU.1, the pivotal transcription factor during microglia development [21]. These hiMGLs showed extremely similar features of primary microglia as scrutinized by transcriptome analysis and exhibited characteristics closer to *in vivo* microglia when co-cultured with mouse primary neurons. Finally, our novel method provides a great opportunity to study the physiological functions of human microglia in the healthy CNS, as well as in the context of neurodegenerative diseases.

## Methods

All reagents used in this study are summarized in Supplementary Table S1.

### Cell culture

#### *Maintenance and culture of human induced pluripotent stem cells (hiPSCs)*

The human iPSC lines 201B7 [22], WD39 [23], and RPC802 (ReproCell Inc., cat# RCRP002N) were cultured as feeder-free cultures. All iPSCs were maintained in 12-well plates (Corning) coated with iMatrix-511 in feeder-free condition. hiPSCs were cultured in StemFit/AK02N (Ajinomoto) medium supplemented with penicillin/streptomycin in a humidified incubator (37 °C, 5% CO<sub>2</sub>). hiPSCs were routinely passaged every week, and the medium was changed every 2 days.

All procedures are following the instruction of the protocol (Human iPS cell culture under feeder-free conditions) published by CiRA (<https://www.cira.kyoto-u.ac.jp/j/research/img/protocol/>) [22].

#### *Establishment of hiPSC clones with inducible PU.1 overexpression*

Genejuice (Sigma-Aldrich, 70967) was used as a transfection reagent. Nine microliters of Genejuice mixed with 200  $\mu\text{l}$  Opti-MEM medium (Gibco™, 31985070) was incubated at room temperature for 5 min; the plasmids were then added (pCMV-HyPBBase\_PGK-Puro 0.4  $\mu\text{g}$ , pG-PB-CAG-rtTA3G-IH 0.4  $\mu\text{g}$ , PB-tet-PHS-*SPI1* 0.8  $\mu\text{g}$ ) followed by another 5-min incubation at room temperature.

Feeder-free hiPSCs were treated with Y-27632 (Wako, 253-00511) (10  $\mu\text{M}$  in AK02N) 1 h before the following procedure: hiPSCs were detached with TrypLE Select (Life Technologies, A12859-01) (0.5 $\times$ , incubate for 10 min at

37 °C); 50,000 cells were counted using Trypan Blue (after being spun down at 1000 rpm for 5 min).

After centrifugation, the supernatant was removed carefully and GeneJuice-DNA mix was added, incubated for 10 min at room temperature. Cells were then seeded evenly into 6 wells of a 12-well plate. The plate was poured with 0.8 ml AK02N medium supplemented with penicillin/streptomycin, 10  $\mu$ M Y-27632, and iMatrix-511. The medium was changed on the next day to remove Y-27632, while hygromycin (20  $\mu$ g/ml) was supplemented for the selection of hiPSCs. When the colonies had grown larger, puromycin (2  $\mu$ g/ml) was added to the medium. The final concentration of hygromycin was 200  $\mu$ g/ml, while that of puromycin was 10  $\mu$ g/ml. Colonies were then mechanically isolated using P10 tips under a microscope. Isolated colonies were seeded into a 24-well plate individually, with a medium supplemented with Y-27632 and iMatrix-511.

#### **Human iPSC-derived microglia (hiMGL) differentiation**

The basic protocol of hiMGL generation (CK protocol) was modified based on several published articles (36, 37). Briefly, the generation of microglia cells from iPSCs is divided into two stages. The first stage is the generation of hematopoietic progenitor cells from iPSCs (hiHPCs; ~ day 18), and the second is the differentiation of microglia-like cells from hiHPCs (day 19~).

Day 0: hiPSCs in 6-well plates were washed with PBS once. Then, 2 ml hiHPC diff. medium supplied with BMP4 (PEPROTECH, 20 ng/ml) and CHIR99021 (Focus Biomolecules, 2  $\mu$ M) was added to each well. Cells were placed in a hypoxia incubator (5% O<sub>2</sub>, 5% CO<sub>2</sub>, 37 °C) until day 6. We noted that the size of colonies seems to affect the efficiency of differentiation, with colonies smaller than usually used for passage resulting in optimal hiMGL differentiation.

Day 2: The whole medium was replaced by 2 ml fresh medium supplied with BMP4 (20 ng/ml), VEGF (Thermo Fisher Scientific, 50 ng/ml), and FGF2 (PEPROTECH, 20 ng/ml).

Day 4: The whole medium was replaced by 2 ml fresh medium supplied with VEGF (15 ng/ml) and FGF2 (5 ng/ml).

Day 6: Cells were collected into 15-ml tubes and centrifuged at 1000 rpm for 5 min. Half of the medium was removed, while the remaining medium (about 1 ml) and cells were returned back to the well. One milliliter of fresh hiHPC medium supplied with VEGF (30 ng/ml), FGF2 (10 ng/ml), SCF (PEPROTECH, 100 ng/ml), IL-3 (PEPROTECH, 60 ng/ml), IL-6 (PEPROTECH, 20 ng/ml), and IWR-1e (Thermo Fisher Scientific, 5  $\mu$ M) was added into each well. From this point, cells were placed in a normoxia incubator (20% O<sub>2</sub>, 5% CO<sub>2</sub>, 37 °C).

Day 9: Cells were supplemented with 1 ml medium as described in day 6.

Day 12: Full volume of medium containing floating cells was collected into 15-ml tubes and centrifuged at 1000 rpm for 5 min. The half volume of the supernatant was carefully removed. Another half of the medium containing all the cells was returned back to the well. Two milliliters of hiHPC medium supplemented with FGF2 (10 ng/ml), SCF (100 ng/ml), IL-3 (60 ng/ml), and IL-6 (20 ng/ml) was added into each well.

Day 15: Cells were supplemented with 1 ml medium as described in day 12.

Day 18: Cells were collected into Falcon tubes and centrifuged at 300 $\times$ g for 5 min. Then, the supernatant was removed carefully and thoroughly. Cells were seeded at 40,000–50,000 cells in 0.8 ml hiMGL diff. medium supplemented with five cytokine cocktail (IL-34 100 ng/ml, TGF $\beta$ 1 50 ng/ml, M-CSF 25 ng/ml, CD200 100 ng/ml, and CX3CL1 100 ng/ml, all from PEPROTECH) each well in 12-well plates. Plates were coated with poly-D lysine (PDL, R&D system) for at least 1 h in advance and washed with PBS three times before use.

Day 19: Half volume of hiMGL diff. medium supplemented with five cytokine cocktails was added into hiMGL culture. After day 19, the half volume of the medium was changed every 2 days. hiMGL was cultured for another week could be used for analysis.

hiHPC diff. medium: StemPro™-34 SFM (1X) (Gibco™, 10639011), GlutaMax (Gibco™, 1X), holo-transferrin (Nacalai tesque, 200  $\mu$ g/ml), L-ascorbic acid (Sigma-Aldrich, 500  $\mu$ M), monothioglycerol (Sigma-Aldrich, 450  $\mu$ M), and penicillin/streptomycin, filtered through a 0.45- $\mu$ m filter.

hiMGL diff. medium: DMEM/F12 (1:1, Gibco™), GlutaMax (1 $\times$ ), NEAA (Thermo Fisher Scientific, 1 $\times$ ), B27 (Thermo Fisher Scientific, 1 $\times$ ), N2 (Thermo Fisher Scientific, 0.5 $\times$ ), ITS-G (Thermo Fisher Scientific, 1 $\times$ ), additional insulin (Sigma-Aldrich, 5  $\mu$ g/ml), monothioglycerol (200  $\mu$ M), and penicillin/streptomycin, filtered through a 0.45- $\mu$ m filter. DMEM can be replaced by the same volume of IMDM (Gibco™).

#### **hiPSC-derived microglia (hiMGL) generation by overexpression of PU.1**

The same procedure as usual, except that doxycycline (1  $\mu$ g/ml) was added into the medium during days 6~18.

#### **Mouse primary hippocampal and cerebellar neurons culture**

Mouse hippocampus and cerebellum were dissected from P0-P2 wild-type C57BL/6J mouse (CLEA Japan, Inc.) brain as previously described [24, 25]. In brief, the dissected brain tissue was dissociated with Trypsin-EDTA (Sigma-Aldrich) for 12 min and triturated with a fire-polished glass pipette. Neural cells were then plated

at a density of 5,000,000 cells/ml on 10-mm cover glasses in 48-well plate with 400  $\mu$ l plating medium (80% DMEM, 10% F12, 10% FBS and penicillin/streptomycin). Cover glasses were coated with poly-D-lysine in advance. On the next day, the medium was changed to a neurobasal medium (Thermo Fisher) supplemented with 1% B27 and L-glutamine; half medium was changed every 2–3 days thereafter.

#### **Transfection of the plasmid DNA expressing GFP- $\beta$ -actin and GCaMP6s into mouse primary neurons**

Lipofectamine 3000 was used as a transfection reagent, and all procedures were following the manufacturer's guidelines.

#### **Co-culture of hiMGL and mouse primary neurons**

hiMGL conditioned medium was collected and centrifuged at 300 $\times$ g for 5 min. The supernatant was carefully transferred into a new tube. hiMGLs were washed with PBS once and incubated at 37 °C for 5 min with 100  $\mu$ l Accutase. Then, hiMGL were detached and collected using their conditioned medium then centrifuged at 300 $\times$ g for 5 min. hiMGLs were then resuspended in a neurobasal medium supplemented with 2% B27 and poured into a 48-well plate of mouse primary neuron cultures. For immunocytochemistry, cells were co-cultured for 3 days, while for morphological analysis and calcium imaging, cells were co-cultured for a week.

#### **Flow cytometry analysis**

hiMGLs were collected using Accutase and then washed twice by FACS solution (PBS + 1% FBS). Next, cells were stained with primary antibodies for 30 min on ice. For the detection of intracellular antigens such as PU.1, cells were incubated with 0.1% Triton-X100 for 10 min on ice before incubating the primary antibody. After FACS solution wash once, cells were stained 15 min on ice with the secondary antibody, followed by another wash with FACS solution wash. FACS analyses were performed using FACS Verse (BD Biosciences, USA). Antibodies used are summarized in Supplementary Table S2.

#### **Quantitative reverse transcription polymerase chain reaction (qRT-PCR)**

Cells were collected in RLT buffer and then homogenized by QIAshredder (Qiagen #79656). Total RNAs were isolated with RNeasy Mini Kit (Qiagen #74106) following the manufacturer's guidelines and then reverse-transcribed to cDNA by PrimeScript™ II 1st strand cDNA Synthesis Kit (Takara, #6210A). qPCR was performed using a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific) and using TB Green Premix Ex Tag II (Takara, #RR820). Primers are described in Supplementary Table S3.

#### **Phagocytosis assay**

For phagocytosis assay, microglia cultured for 7 days after replating were transferred onto 10-mm cover glasses in a 48-well plate. Cover glasses were coated with PDL for at least 1 h before use. Cells were placed in the incubator overnight before applying the phagocytosis assay.

Before the phagocytosis assay, the Latex beads and fibrillary amyloid beta were mixed with FBS for 30 min in a 37 °C incubator. Both reagents were diluted one-fifth. Both final concentrations of Latex and fibrillary amyloid beta were 1:1000. Then, 5  $\mu$ l per vial was added to each well directly. The culture plate was incubated at 37 °C for 1 h, then fixed with 4% PFA following wash twice with PBS and kept in 4 °C for future analysis.

#### **Immunocytochemistry**

Cells were fixed with 4% PFA for 15 min, followed by two PBS washes. For immunocytochemistry, the blocking was done using PBS containing 0.4% Triton X-100 and 1.5% FBS. Primary and secondary antibodies were also diluted in this solution. Cells were incubated with primary antibodies at 4 °C overnight and then washed twice with PBS for 15 min. Incubation with the secondary antibodies lasted 1 h at room temperature. Cells were finally washed twice with PBS and mounted with PermaFluor mounting medium (Thermo Fisher Scientific).

#### **Western blot**

hiMGLs and hiPSCs were lysed in cold RIPA buffer. Complete® Protease Inhibitor and Phosphatase Inhibitor were added freshly to RIPA buffer directly before use. Cell lysates were homogenized by passing through a 1-ml syringe, followed by centrifugation for 30 min at 15,000 rpm at 4 °C. Supernatants were collected and stored at – 80 °C. Protein concentration was determined using a BCA Protein Assay Kit. Ten micrograms of total protein was loaded and separated by 10–20% Extra PAGE gels (Nacalaitesque, Japan) in SDS running buffer. Gels were transferred to nitrocellulose membranes using a Trans-Blot Turbo system. The membranes were blocked with 5% milk in TBST for an hour at room temperature, followed by incubation with  $\alpha$ -tubulin antibody or DAPI2 antibody at 4 °C overnight. The next day, the membranes were incubated with the corresponding Odyssey secondary antibody diluted in TBST and CanGetSignal buffer (TOYOBO, Japan) (1:1) for an hour at room temperature. Images were captured and analyzed using the Odyssey Imaging system (LI-COR Biosciences, USA).

#### **Analysis of dendritic spines**

After co-culturing with hiMGLs for 2 weeks, primary neurons transfected with GFP- $\beta$ -actin [26] were



immunostained with anti-GFP antibody and captured using a confocal microscope system (Zeiss, LSM700) equipped with a  $\times 63$  objective lens (Zeiss, Plan-Apochromat, NA 0.8). Images were analyzed by ImageJ (Ver.2.0.0-rc-69/1.52s).

### Calcium imaging

Calcium imaging was performed as described previously [27]. Primary neurons were transfected with a plasmid expressing GCaMP6s (Addgene plasmid # 51084), and after co-culture with hiMGLs for 2 weeks, calcium images were taken using a IX80 microscopic system (Olympus, Japan) with a 0.75-s step for 4 min. Images were analyzed using ImageJ. Videos were taken by stacks and then merged by Z-projections, and  $\Delta F/F$  values were calculated with the fluorescence intensity in the region of interest (usually set on the neuronal cell body).

### Statistics

Statistical analyses and graph creation were done using the GraphPad Prism10 software (Ver.8.2.0). The Mann-Whitney test was used for the statistical analysis of qRT-PCR, western blot, and calcium imaging; the nested *t*-test was used for phagocytosis assay; 2-way ANOVA was used for the analysis of dendrites ( $n = 3$  per experiment, 3 independent experiments) ( $*p < 0.05$ ;  $**p < 0.01$ ;  $***p < 0.001$ ; n.s.: not significant).

### Bulk mRNA-seq analysis

Poly(A)+ RNA was selected and converted to a library of cDNA fragments (mean length, 350 bp) with adaptors attached to both ends for sequencing using the KAPA mRNA Capture Kit (KK8440; Kapa Biosystems), KAPA RNA HyperPrep Kit (KK8542; Kapa Biosystems), KAPA Pure Beads (KK8543; Kapa Biosystems), and SeqCap Adapter Kit A (Roche) according to the manufacturer's instructions. The cDNA libraries were quantified using the KAPA Library Quantification Kits (KK4828; Kapa Biosystems) and were sequenced using an Illumina HiSeqX to obtain 150-nucleotide sequences (paired-end). Data of mRNA-seq (*fastq* file format) were quality-checked, and low-quality reads (score  $< 30$ ), adapter sequences, and overrepresented sequences such as poly-A chain were trimmed using the *Trim Galore!* (ver.0.4.0). The remaining reads were mapped to the *Homo sapiens* (hg19) genome using the *Hisat2* (ver.2.2.2.0) [28], and the output file (BAM file format) was summarized using the *featureCounts* (1.5.2) [29]. The summarized data were processed by the *DESeq2* (3.3.0) for estimating their size factors, followed by the removal of reads not expressed in any of the samples. Subsequently, the data were normalized by varianceStabilizingTransformation (vst).

For mRNA-seq analysis, we also included deposited data of previous studies in GEO (<https://www.ncbi.nlm.nih.gov/geo/>) and DDBJ (<https://www.ddbj.nig.ac.jp/>) as follows: Monocytes, AH1 iMGL, and adult and fetal microglia in GSE89189 [16].

RNA sequencing data have been deposited in the Gene Expression Omnibus of NCBI (<https://www.ncbi.nlm.nih.gov/geo/>) under accession no. GSE178284.

## Results

### Determination of crucial cytokines and small molecules for primitive hematopoietic progenitor differentiation

To obtain human microglia-like cells from hiPSCs in vitro, we aimed to develop an efficient protocol using multiple cytokines, according to previously published articles [14–17]. Prior approaches were conceived by the idea that microglia can be differentiated from primitive hematopoietic progenitor cells (HPC), which are derived from the yolk sac originating in the posterior mesoderm [18]. For the induction of primitive HPCs, multiple cytokines, in addition to manipulating the BMP4 and Wnt signaling, were applied in these methods.

To define which signaling pathways are necessary and sufficient for inducing posterior mesoderm formation in vitro, we picked up several candidate reagents (BMP4, CHIR99021, VEGF, TGF $\beta$ 1, Activin A, SB431542, FGF2) from previous literatures on mesoderm development [30, 31]. Firstly, through immunostaining of mesodermal markers such as brachyury, we confirmed that only CHIR99021 (CHIR), a GSK-3 inhibitor; as well as BMP4, was necessary and sufficient to induce mesoderm-like characters in hiPSCs in vitro (Supplementary Fig. S1a-d). Since VEGF, a key regulator of blood vessel formation and hematopoiesis, and Activin A, which is an agonist of TGF- $\beta$ /Smad signaling, were applied in multiple protocols for inducing posterior mesoderm from hiPSCs in previous reports [15–17, 32], we next tested if they were necessary for the first 2 days through qRT-PCR. Although the expression of *MSGNI*, a paraxial mesoderm marker, was reduced when Activin A was added, there was no difference in other mesoderm markers [33]. Moreover, the addition of VEGF did not change mesodermal marker genes (Supplementary Fig. S1d). As a result, we decided to limit the additives to BMP4 and CHIR for the first 2 days during the mesodermal differentiation.

Then, during the differentiation to primitive HPCs, we found that besides hematopoietic cells, cardio-lineage cells were also generated simultaneously, which resulted in a lower efficiency of HPC production than expected. According to previous studies, Wnt signaling could be a vital determinant of the balance between the cardiac and hematopoietic lineages [34–36]. Notably, the non-canonical Wnt pathway is beneficial for the myeloid

lineage, whereas the canonical Wnt signaling regulates non-myeloid hematopoiesis, including T and B cell development [35, 37, 38]. We first tried two small molecules, IWR-1e and IWP-2, which are both inhibitors of Wnt signaling with distinct mechanisms. IWR-1e is a stabilizer of  $\beta$ -catenin degradation complex, which leads to the specific inhibition of the canonical Wnt pathway, while IWP-2 binds to porcupine to inhibit Wnt secretion and processing and therefore inhibits both canonical and non-canonical Wnt signaling. As measured by qRT-PCR, we found that treatment with IWR-1e during days 6–12 could efficiently induce primitive HPC differentiation (Supplementary Fig. S2). The mRNA expression level of *GYP A*, a specific marker for the primitive hematopoietic lineage (51), which would further differentiate to microglia cells, and *GATA2*, a key transcription factor for the commitment toward the hematopoietic lineage instead of the cardiac lineage [37], was much more upregulated by IWR-1e than IWP-2. Therefore, IWR-1e was included for an efficient primitive hematopoietic lineage induction from day 6. The combination of these cytokines and small molecules (referred to as “CK protocol”) induced the successful differentiation of hiPSCs to primitive HPCs.

#### **PU.1 overexpression in iPSC-derived mesoderm potentially induces microglia progenitor cells**

Although we succeeded in deriving microglia cells from multiple hiPSC lines through the CK protocol, we found an important variability of differentiation efficiency among different hiPSC lines, even between control hiPSCs from healthy individuals. To solve this problem, we next developed a novel method to derive microglia cells from hiPSCs through overexpression of *SPI1*, which encodes PU.1, one of the key transcription factors for microglia development, during hematopoiesis. To enforce the inducible overexpression of PU.1 in hiPSC-derived lineages, we transduced an inducible *SPI1* expression plasmid, as well as plasmids expressing reverse tetracycline transactivator (rtTA) and hyperactive piggyback transposase (Fig. 1A). Following selection with puromycin and hygromycin, we successfully obtained a couple of clones for each of the three independent hiPSC lines used (RPC802, 201B7, and WD39), where all expression plasmids were integrated by a non-viral-based approach.

Because the expression of endogenous *SPI1* mRNA, as well as that of *IRF8* (Supplementary Fig. S3a), another critical transcription factor for microglia differentiation, started at day 6 in CK protocol, we decided to induce PU.1 expression on day 6 in our newly developed protocol (hereafter referred to as “PU protocol”) through addition of doxycycline (Dox) (Fig. 1B). qRT-PCR showed that *SPI1*, as well as  *$\beta$ -geo*, which is a congruent

transcript of *SPI1* (Fig. 1A), was increased more than 50 times in Dox-treated cells on day 7, compared with those without Dox treatment (Fig. 1C). In contrast, the mRNA level of the 3'UTR of *SPI1*, which was not included in the PU.1 expression plasmid, was barely changed following Dox treatment, confirming that the increased expression of *SPI1* was derived from the exogenous, not endogenous, *SPI1* transcript (Fig. 1C). A similar induction pattern of *SPI1* and  *$\beta$ -geo* mRNAs was observed in two other hiPSC lines, 201B7 and WD39, upon Dox treatment (Supplementary Fig. S3b). Since the subsequent differentiation was comparable among these iPSC lines carrying the inducible *SPI1* gene, we mostly used RPC802 hiPSCs in the following analyses.


About 1 week after Dox treatment, extruding bubble-like structures, from which a large amount of HPCs (also putative microglia progenitor cells, hereafter hiHPCs), could be observed more frequently in PU protocol (Fig. 1D, Supplementary Fig. S4). Interestingly, this kind of multicellular structure was barely observed in the CK protocol (Fig. 1D, Supplementary Fig. S4). The number of hiHPCs in the culture medium upon PU protocol was more than double compared with that in the CK protocol. Furthermore, those floating cells could be collected during more than three consecutive days in PU protocol, whereas such cells could be collected only once or twice in the CK protocol (Fig. 1E). Moreover, an extended culture with CK protocol led to an extremely small cell number, associated with a morphological change of microglia progenitors as well. These results revealed a clear advantage of PU protocol, compared with the CK protocol.

After re-plated to culture dishes for another week (day 25), the hiHPCs started to show microglia-like morphology, and further long culture led to a more ramified shape at day 39, similar to homeostatic sensing microglia (Fig. 1F). Hereafter, the terminal differentiated microglia-like cells in the PU protocol were referred to as (PU-) human induced microglia-like cells (hiMGLs).

#### **High purity PU-hiMGLs are comparable to CK-hiMGLs**

The overexpression of PU.1 during hematopoiesis generated hiHPCs efficiently (Fig. 1). However, we were not sure whether PU.1 could enhance the efficiency of microglia terminal differentiation. Therefore, we next tried to compare the efficiency and purity of hiMGL derivation between the PU and CK protocols.

While the percentage of hiHPCs expressing CD34 and CD43 above 90% were comparable in both methods (Fig. 2A), the percentage of CD11b and CD45-positive cells showed a significant difference between CK and PU protocols (Fig. 2B). In PU protocol, over 90% of the floating hiHPCs (considered to be microglia progenitor cells) were CD11b/CD45-positive



**Fig. 1** (See legend on next page.)

(See figure on previous page.)

**Fig. 1** Differentiation of hiMGLs from hiPSCs through overexpression of PU.1 transcription factor. **A** Schematic diagram of the tet-on inducible expression vector of *SP11* and plasmids expressing hyperactive piggyBac transposase (HyPBBase) or reverse tetracycline transactivator (rtTA). **B** Protocol for generating hiMGLs from hiPSCs. For PU protocol, doxycycline (DOX) was added into the medium from days 6 to 18. **C** qRT-PCR data about the expression level 1 day after the DOX was added (day 7). Compared with the groups with no DOX (Ctrl), *SP11*, as well as congruent  $\beta$ Geo, was strikingly upregulated after DOX treatment for 24 h ( $n = 3$  independent clones). There was no observed difference of the 3'UTR of the *SP11* gene, which is not included in the *SP11* expression plasmid, indicating that the high expression level of *SP11* on day 7 was exogenous. ns, not significant; \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ . All data are expressed as mean  $\pm$  SEM. SEM, standard error of the mean. **D** Bubble-like structures were observed in the PU protocol, not in the CK protocol. Scale bar, 200  $\mu$ m (left) and 50  $\mu$ m (right). **E** More than three times of hiHPC (microglial progenitor cells) could be harvested (days 18, 22, 26) by using the PU protocol, compared to the CK protocol ( $n = 3$  independent experiments). **F** Representative images of hiMGLs. iMGLs acquired more ramified morphology 3 weeks after re-plating of hiHPCs (day 39) than those from the shorter culture (day 25). Scale bar, 50  $\mu$ m (upper) and 25  $\mu$ m (lower)

on day 16, compared with about 60% in CK protocol, whereas this percentage in PU protocol was about 27% without neither Dox nor IWR-1e treatment (less efficient for primitive hematopoietic progenitors). These results indicated that posterior mesodermal patterning is crucial for the subsequent differentiation of microglial progenitor cells. We further examined the expression of CD235a, a specific marker of the primitive hematopoietic lineage [35], along with a hematopoietic stem cell marker KDR (also known as VEGFR2) in the adherent mesodermal cell population. Notably, we found that without blocking the Wnt/ $\beta$ -catenin pathway,  $\sim 16\%$  of mesodermal cells were CD235a/KDR-positive, suggesting that these cell population differentiated into a lineage different from the primitive hematopoietic lineage (Fig. 2C) [35]. In contrast, the appropriate inhibition of canonical Wnt signaling successfully gave rise to  $\sim 60\%$  CD235a/KDR-positive mesodermal cells (Fig. 2C, Supplementary Fig. S5, S6). Due to the higher purity and greatly improved yields of microglial progenitor population in PU protocol, we thereafter mainly used PU-hiMGLs, unless otherwise noted.

We next tested the microglial purity of hiMGLs after hiHPCs were re-plated into culture dishes and cultured for another week. For further comparison with a distinct myeloid population, we used THP-1 cells, a human monocytic cell line, as another myeloid control with different destiny. Although most hiMGLs and THP-1 cells (95%) highly expressed the hematopoietic cell marker CD45, only hiMGLs expressed high levels of myeloid lineage markers (IBA1, PU.1, and CX3CR1), as well as microglia-specific markers (TMEM119 and P2RY12), compared with THP-1 (Fig. 3A). Especially, DAP12 and TREM2, which are specifically expressed in microglial cells, were highly expressed in  $\sim 85\%$  and  $\sim 95\%$  of hiMGLs, respectively, while almost no THP-1 cells expressed them (Fig. 3A, Supplementary Fig. S7).

Next, we confirmed by immunocytochemistry that most cells re-plated into culture dishes expressed microglia-specific markers, IBA1, TMEM119, CX3CR1, P2RY12, DAP12, and TREM2, with their nuclei co-

stained with PU.1 (Fig. 3B). Furthermore, western blotting showed that DAP12 and DAP10 proteins were only expressed in hiMGLs, not in hiPSCs (Fig. 3C). These data implied that the PU protocol could successfully generate hiMGLs specifically expressing microglial markers with high purity in a short period of time.


#### PU.1 overexpression does not affect the transcriptional profile of hiMGLs

While PU.1 is a crucial transcription factor for microglia differentiation, a minor variant of PU.1 has been associated with the pathogenesis of AD [39], suggesting that long-term overexpression of PU.1 might result in an alteration of microglia-like cells similar to those in brains of AD patients. Next, we performed a comprehensive gene expression analysis to assess how close hiMGLs related to primary microglia cells collected from a human brain, and whether PU.1 overexpression would affect the characteristics of microglia at transcription levels compared with those in the CK protocol.

Total RNAs of hiMGLs were purified on day 25 in both CK and PU protocols, and their gene expression profiles were compared with monocytes, adult and fetal primary human microglia, and other hiPSC-derived microglia-like cells, which were published previously [16, 17]. RNA sequencing followed by principal component analysis (PCA) and hierarchical clustering analysis visualized by heatmap revealed that the transcriptional profile of hiMGLs was close to those of microglia-like cells derived from another protocol [16] and primary microglia, whereas monocytes showed far different profiles (Fig. 4A–C). These results clearly demonstrated that hiMGLs resembled human primary microglia and could be used as a cellular model for studying human microglia in both physiological and disease conditions.

Furthermore, we analyzed in detail the genes differently expressed in hiMGLs derived from the CK protocol and PU protocols. First, we picked up the genes mostly expressed by hiMGL (Fig. 4D). Worth mentioning, except some housekeeping genes and genes involved in the complement system, *SPP1*, which encodes a protein called osteopontin (OPN), was highly expressed in





**Fig. 2** (See legend on next page.)


(See figure on previous page.)

**Fig. 2** Primitive hematopoietic lineage induction by PU.1 overexpression. **A** Flow cytometry analysis of the differentiation pattern of hiHPCs. Markers of hematopoietic progenitor cells, CD34 and CD43, were analyzed in floating hiHPCs from day 4 to day16 (several thousand cells per independent experiment). **B** Flow cytometry analysis of the differentiation pattern of hiHPCs. Markers of myeloid cells, CD11b and CD45, were analyzed in floating hiHPCs from day 4 to day16 (several thousand cells per independent experiment). **C** Flow cytometry analysis of the differentiation pattern of hemangioblasts. Markers of the primitive hematopoietic lineage, KDR and CD235a, were analyzed in attached mesodermal cells at day16 (several thousand cells per independent experiment)


hiMGLs [38]. Osteopontin was reported to be involved in the polarization, chemotaxis, and phagocytosis functions of immune cells [40]. Furthermore, in addition to the change of microglia features, OPN can also be secreted by microglia, promoting the proliferation of neural precursor cells [41]. Recently, OPN was also reported as a brain region-specific microglial marker,

which can affect the phagocytic function of microglia [42–44].

Next, we compared the expression level of various microglia markers between CK- and PU-hiMGLs. Interestingly, PU.1 overexpression seemed to downregulate the expression of inflammatory reaction genes, such as *IRF4*, *IL-1a*, and *CIQA* (Fig. 4E). This impression was



**Fig. 3** High purity of microglial-like cells in hiMGLs derived by the PU protocol. **A** The purity of iMGLs was analyzed by flow cytometry at day 25 (also see Supplementary Fig 7). Whereas the marker of pan myeloid cells (CD45) was expressed equally by both hiMGLs and monocytic THP-1 population (more than 90%), microglia-specific markers (IBA1, CD11b, P2RY12, TMEM119, CX3CR1, PU.1, DAP12, and TREM2) were enriched in hiMGL compared to THP-1 (several thousand cells per each independent experiment). **B** Immunostaining of microglia-specific markers (IBA1, TMEM119, DAP12, CX3CR1, P2RY12, and TREM2) co-stained with PU.1 and Hoechst 33342 on hiMGLs at day 25. Scale bar, 75µm. **C** Western blot of DAP12 was performed using cell lysate of iPSC and PU-hiMGL. hiPSCs showed a low expression of DAP12 and its highly homologous DAP10 until they were differentiated into iMGLs. Both DAP12 and DAP10 were increased by ~ 50% and ~ 100% in cell lysates of hiMGL compared with those of hiPSC ( $n = 3$  independent experiments)



further reinforced by the comparison of upregulated and downregulated genes between PU.1 overexpressing cells and their counterparts (Supplementary Fig. S8). Gene Ontology (GO) term enrichment analysis indicated that PU.1 overexpression reduced the expression level of genes involved in response to antigens, such as viruses

and bacteria, while genes linked to neurodegenerative diseases were barely affected. This negligible effect of PU protocol on the character of homeostatic microglia is an important observation indicating that this PU protocol can be applied for studying human microglia in the context of neurodegenerative diseases.

### PU-hiMGLs exhibit physiological microglial functions

Microglia sense the alteration of the nearby environment and remove unwanted materials which otherwise would injure brain neural cells [45]. To confirm the physiological function of hiMGLs, we investigated the following microglia-specific features: phagocytosis, secretion of inflammatory cytokines, and formation of the inflammasome.

Clearance of pathogens or cell debris is one of the most notable functions of microglia, as suggested by the observation that efficient engulfment of fibrillar  $\beta$ -amyloid ( $A\beta$ ) by microglia is compromised in the brain of AD patients. To confirm the phagocytic ability of hiMGLs, we used 1.0  $\mu$ m latex beads and fibrillar  $A\beta$ 1–42, both conjugated with allophycocyanin (APC) fluorescence. Since these particles might attach to the cell surface instead of entering inside the hiMGLs, we used a phagocytosis inhibitor, cytochalasin D (CCD), which prevents actin polymerization. We found that after treatment with CCD for 2 h before the addition of  $A\beta$  peptide or latex beads, hiMGLs lost almost all of their phagocytic ability, from  $\sim$  30% APC-positive cells to  $\sim$  5% with latex beads and  $\sim$  10 to  $\sim$  5% with  $A\beta$  peptide, indicating that latex beads and  $A\beta$  peptide were successfully endocytosed in this assay condition (Fig. 5A).

Cytokines released by microglia are vital regulatory factors of the innate immune system. Thus, the secretion of inflammatory cytokines by hiMGLs was measured following treatment with lipopolysaccharide (LPS) for 3 h. qRT-PCR showed that the expression of five inflammatory cytokine genes, *IL-1a*, *IL-1 $\beta$* , *IL-6*, *IL-10*, and *TNF $\alpha$* , were strongly upregulated by LPS, especially *IL-1 $\beta$*  that was upregulated about 200 times (Fig. 5B). Many of these cytokines have been reported to be elevated in the pathological condition AD [46]. Expression of *NFKB1* was also upregulated five times with LPS treatment, indicating the activation of NF- $\kappa$ B signaling (Fig. 5B). Since abnormal NF- $\kappa$ B signaling activation was reported in AD, we believe that these LPS-stimulated hiMGLs might be used for AD research in future studies [47]. Surprisingly, although *SPI1* was not significantly upregulated, *IRF8*, which is another important transcription factor for myeloid cells, was highly elevated following treatment with LPS (Fig. 5C) [48].

Recently, the inflammasome has been reported to be involved in the pathogenesis of two AD-related pathological hallmarks, tau and  $A\beta$  [49, 50]. Considering the application of hiMGLs in future studies on AD, we next tested the formation of the inflammasome in hiMGLs. Interestingly, we found that the levels of mRNAs encoding two key proteins of the inflammasome (ASC and NLRP3) and IL-1 $\beta$  were upregulated in hiMGLs after co-treatment with  $A\beta$  and LPS (Fig. 5D). However, treatment with LPS alone was sufficient to upregulate the expression of IL-1 $\beta$ , while the increase of inflammasome-

related genes (*ASC* and *NLRP3*) was observed with  $A\beta$  alone or  $A\beta$ /LPS, but not LPS alone (Supplementary Fig. S9, S10). These results confirmed that the hiMGLs were able to form the inflammasome under inflammatory conditions relevant to human primary microglia.

Together, LPS treatment led to NF- $\kappa$ B-dependent up-regulation of pro-IL-1 $\beta$ , whereas  $A\beta$  treatment alone does not induce the expression of IL-1 $\beta$ . In contrast, inflammasome activation, aggregation of NLRP3 and ASC, was induced fully with  $A\beta$  stimulation following the prime signaling such as LP S[51] but was also partially observed with  $A\beta$  stimulation alone.


### Development of a novel culture platform containing hiMGLs and primary neurons to mirror the physiological circumstances in the CNS

Impaired microglial functions have been reported in various neurodegenerative diseases, such as AD, ALS, and Parkinson's disease [52, 53], which affect the neural network in the complex context of the human CNS. To examine if hiMGLs can be applied to more suitable pathophysiological environments, we developed a novel culture platform, where human hiMGLs were co-cultured with mouse primary neurons (Fig. 6A). Because we sought to assess the effect of microglia on functional mature neurons, we used mouse primary neurons instead of human iPSC- or fibroblast-derived neurons, which are well-known for their immature features.

First, to examine the morphological alteration of hiMGLs, we performed immunocytochemistry of the cultures using antibodies against IBA1, a microglia-specific marker. Strikingly, hiMGL morphology changed from amoeboid to ramified after co-culture with primary hippocampal neurons for two weeks. In addition, the area of hiMGL cytoplasm was increased by  $\sim$  10-folds in the co-culture, implying that hiMGLs shifted to a sensing mode (Fig. 6B). Furthermore, a similar morphological alteration of hiMGLs was observed in co-culture with mouse cerebellar neurons (Supplementary Fig. S11a). These results suggested that some neuronal factor(s) could regulate hiMGL features, independently of the brain's regional origin. Importantly, immunostaining with STEM121, an antibody against human-specific cytoplasm antigen, confirmed that these microglia-like cells in the co-culture system were human-derived, different from mouse primary microglia cells (Fig. 6C).

In early development, microglia play a key role in pruning supernumerary synapses and dendritic spines [54, 55]. Recently, microglia have been reported to control stimulus-dependent spine structural changes at synapses in adult mouse brains [56, 57]. To further explore how hiMGLs affect neuronal morphology and function, we analyzed dendritic spines and neuronal activity. For clearer effects of hiMGLs, we used mouse





(See figure on previous page.)

**Fig. 5** Evaluation of microglial physiological functions in PU-hiMGLs. **A** Phagocytosis analysis using 1.0- $\mu$ m Latex beads and fibrillar A $\beta$ 1–42, both conjugated with APC fluorescence. Representative images of hiMGLs with and without phagocytosis inhibitor, CCD. Scale bar, 200  $\mu$ m. Quantification of hiMGLs showing phagocytosis of fluorescence. Two-way ANOVA showed a significant difference between the groups with and without CCD.  $F(161, 648) = 4.2, p = 0.000835$  for A $\beta$ 1–42 and  $F(161, 547) = 3.6, p = 0.000927$  for Latex beads, followed by post hoc test  $***p < 0.001, n = 3$  independent experiments using  $n = 3$  independent clones. **B** Levels of cytokine gene expression in iMGLs were quantified by qRT-PCR following 3-h LPS treatment.  $*p < 0.05; **p < 0.01; ***p < 0.001$ . All data are expressed as mean  $\pm$  SEM ( $n = 3$  independent clones with  $n = 2$  independent experiments). **C** The expression level of two key microglial transcription factors (*SPI1, IRF8*) was evaluated by qRT-PCR after 3-h LPS treatment. ns, not significant;  $***p < 0.001$ . All data are expressed as mean  $\pm$  SEM ( $n = 3$  independent clones with  $n = 2$  independent experiments). **D** Composition of the inflammasome (NLRP3, ASC, IL-1 $\beta$ ) was confirmed by immunostaining after LPS and A $\beta$ 1–42 co-treatment. Scale bar, 100  $\mu$ m. SEM, standard error of the mean


primary neurons, as human microglia can be successfully transplanted into mouse brains without any developmental disturbance albeit species difference [58]. For the analysis of dendritic spines, we transfected mouse primary neurons with a plasmid expressing sparsely  $\beta$ -actin-GFP fusion protein to visualize spine morphology in the cultures (Fig. 6D). Then, we quantified the dendritic spines classified into six groups: filopodia, long thin, thin, stubby, mushroom, and branched. Surprisingly, the number of spines in primary hippocampal neurons was significantly increased by  $\sim 1.5$ -folds in co-culture with hiMGLs, which was mostly contributed by spines with long thin and branched morphology (Fig. 6E). Although not reaching statistical significance, the number of mushroom spines showed a tendency to increase in co-culture with hiMGLs, indicating that hiMGLs could promote the maturation of dendritic spines in mouse primary hippocampal neurons (Fig. 6D, E). Unexpectedly, however, we were unable to find significant effects of hiMGLs on mouse cerebellum neurons (Supplementary Fig. S11). This discrepancy could be due to different functional characteristics of microglia regarding distinct regions of the brain. In agreement with such an idea, microglia show different densities and characteristics in different brain regions, although these cellular and molecular particularities remain to be elucidated [44, 59]. To evaluate the spontaneous neuronal activity, we transfected mouse primary neurons with a plasmid expressing the fluorescent calcium indicator GCaMP6s under the neuron-specific *Synapsin 1* promoter. Neurons co-cultured with hiMGLs showed a reduced spike frequency and a higher maximum activity than those cultured in the absence of hiMGLs (Fig. 6F), suggesting that besides structural alteration of spines, the neuronal activity is modulated by hiMGLs.

In summary, we demonstrated that hiMGLs could be used to investigate physiological neuronal functions through a novel *in vitro* system, which comprised primary neurons and hiMGLs. This platform could be applied to study neuron-microglia interactions and pathophysiological mechanisms when co-culturing with patient-derived cells carrying relevant gene mutations.

## Discussion

Since Pío del Río-Hortega described oligodendrocytes and microglia together as the “third element” of CNS in 1919, over a century has passed. While the microglial cellular origin remained elusive for a long time, its ontogeny has been convincingly demonstrated by recent findings pointing to the yolk sac, which originates in the extra-embryonic mesoderm, in contrast to the other cellular neural elements that arise from the neuroectoderm [18]. However, as most studies were accomplished using postmortem specimens or non-human materials thus far, there is an urgent and strong need to develop a new method for providing a sufficient number of human microglia. In the present study, in relation to the cellular ontogeny of microglia, we developed a novel method to derive microglial cells from hiPSCs faster and more efficiently than with previously established protocols. Especially, to drive cellular ontogeny into primitive hematopoietic cells, we used small chemicals regulating the Wnt pathway at appropriate time points. By forcing the expression of the transcription factor, PU.1, we successfully harvested a large amount of microglia within three weeks. Transcriptome analyses demonstrated that our hiMGLs were transcriptionally very close to human primary microglia (Fig. 4). Even without cell sorting, the purity of these hiMGLs was over 90%, which was confirmed by both flow cytometry and immunostaining (Fig. 3). Regarding cellular functions, hiMGLs could phagocytose latex beads and A $\beta$  peptide, which were further confirmed by the phagocytosis inhibitor, CCD (Fig. 5A). Major upregulation of inflammatory cytokine expression in hiMGLs was observed after 3-h LPS treatment (Fig. 5B), while the incubation with A $\beta$  peptide and LPS also induced the inflammasome (Fig. 5D). Furthermore, in the co-culture model, calcium imaging showed that mouse primary neurons co-cultured with hiMGLs had more dendritic spines and stronger regular spikes (Fig. 6), indicating that hiMGLs helped neurons to mature and form appropriate functional networks.

Only a few methods have been reported for deriving microglia-like cells from human iPSCs since the first report in 2016 [14–17], and most of them demand a



**Fig. 6** Reciprocal biological effects in co-culture of hiMGLs and primary neurons. **A** Schematic diagram of the co-culture system. **B** Representative images of immunostaining with IBA-1 and βIII-tubulin in co-culture or hiMGLs alone. After co-culture with primary neurons for 1 week, hiMGLs exhibited a more ramified morphology, which was not observed in hiMGL culture alone. In addition, hiMGLs in co-culture showed a larger area than those in single culture ( $n = 32$  in single culture, 26 in co-culture; 3 independent experiments). Scale bar = 15µm.  $***p < 0.001$ . **C** Mouse primary neurons were transfected with actin-GFP plasmid and then immunostained with anti-STEM121, IBA1, and GFP antibodies. Scale bar = 50µm. **D** hiMGLs showed attaching to axons and dendrites. Scale bar = 10µm. **E** The number of dendritic spines was increased in co-culture with hiMGLs. High-magnification images showed that neurons co-cultured with hiMGLs had more matured spines (mushroom and so on), while neurons in single culture had much less mature dendritic spines. Scale bar = 2µm. Spines were categorized into six groups and quantified. Quantification showed much more spines in the co-cultures than single cultures ( $n = 25$  in single culture, 35 in co-culture; 3 independent experiments). ns, not significant;  $*p < 0.05$ . All data are expressed as mean  $\pm$  SEM. **F** Primary neurons co-cultured with hiMGLs showed large spikes and reduced frequency. Representative images of calcium response in the co-culture (hiMGLs) or neurons alone (CTRL). Quantification of maximum  $\Delta F/F$  and spike frequency indicated that hiMGLs could raise the regularity of neuron's activity ( $n = 16$  in single culture, 18 in co-culture; 3 independent experiments).  $*p < 0.05$ ;  $**p < 0.01$ . All data are expressed as mean  $\pm$  SEM. SEM, standard error of the mean

relatively long culture period (about two months) combined with cell sorting by flow cytometry.

In contrast, we showed in this study that human microglia cells could be generated from hiPSCs in an efficient and simple way through overexpression of PU.1, a vital transcription factor for microglia development, without cell sorting and any feeder cells. By using this more efficient and economic protocol, a large number of microglia, enough for RNA extraction or protein purification, could be harvested even from a small number of starting hiPSCs (approximately 120-folds), compared with other protocols (at most ~ 40 folds). hiMGLs could be derived within 3 weeks and maintained over a long duration (> 2 months), whereas other protocols sometimes took ~ 60 days. In addition to the known association of PU.1 with inflammatory responses, genome-wide association studies have shown that the expression levels of PU.1 contribute to late-onset AD [60, 61]. Therefore, we were worried that the transient overexpression of PU.1 would cause an inflammatory activation in hiMGLs. However, the transcriptome profile indicated that PU-hiMGLs have lower expression levels of genes related to inflammation than CK-hiMGLs. Importantly, we have confirmed that hiMGLs could be applied to various functional analyses of microglial physiology.

To our annoyance, the ontogeny of microglia and macrophages resembles each other in their early development. Especially, PU.1 is reportedly crucial for the differentiation of both cell types [21, 62]. Chen et al. recently developed a similar method to derive microglia-like cells from iPSCs by transduction of both PU.1 and C/EBP $\alpha$  [63]. Interestingly, these master regulators have been used for trans-differentiation of macrophage-like cells from human lymphocytes and fibroblasts [64, 65]. Considering that microglia and macrophages were derived from primitive and definitive hematopoietic progenitors, respectively, our strategy had a great advantage for microglial-like cells in that overexpression of PU.1 was initiated after the induction of primitive hematopoietic progenitors. In contrast to our study, Chen et al. transduced two transcription factors (PU.1 and C/EBP $\alpha$ ) into iPSCs by lentiviruses. Considering that viral infection might cause an immune reaction, non-viral transduction methods, especially via inducible expression by Dox treatment, could be preferable as shown in this study. hiPSC clones bearing *SPI1* expression plasmid could also be stored as usual to reduce the variations among batches. Another important difference between Chen et al.'s method and ours is the number of transcription factors manipulated and the timing of induction during derivation: both *SPI1* and *CEBPA* were ectopically expressed in hiPSCs in Chen et al.'s strategy, while only *SPI1* was induced in the posterior mesoderm in our study, which we thought might lead to a much

larger number of microglia progenitor cells that could be harvested. Analyzed by flow cytometry, our hiMGLs showed a higher expression of CD11b and CX3CR1. Furthermore, although treated only with LPS instead of LPS and IFN- $\gamma$ , the expression of IL-10 was upregulated in hiMGLs, which contrasted with Chen et al.'s data. Providing that IL-10 is reported to be an anti-inflammatory cytokine, we hypothesized that this was related to our transcriptome data, in which PU.1 overexpression led to lower expression of genes related to inflammation (Fig. 4).

Microglia have been reported to affect neuronal morphology and function in vivo and in vitro [66, 67]. In this study, to understand these microglia-neuron physiological interactions, we have established the experimental system by co-culturing hiMGLs and primary neurons. Here, we showed that hiMGLs exhibited a strikingly more ramified and complex morphology in this co-culture system than in culture alone. Conversely, hiMGLs also changed the characteristics and activity of primary hippocampal neurons, although the detailed molecular mechanism remained to be determined. In a previous study, when microglia were depleted by PLX5662, a CSF1R inhibitor, neurons had fewer responses to odors, indicating that they were not properly connected to neural circuits [5]. Furthermore, in the mice treated with PLX5662, neurons had a lower spine density. In our co-cultured system with hiMGLs, primary neurons exhibited more dendritic spines, suggesting that microglia could help form new synapses or stabilize the existing spines. Indeed, recent studies have shown that microglia influence synaptic formation and maturation during development by direct contact and by releasing factors such as fractalkine, IL-10, and BDNF [56, 67–69]. In this regard, the contradictory effect of hiMGLs on spine density between the hippocampus (Fig. 6E) and cerebellum (Supplementary Fig. S11) might result from a possible different expression of receptors between these neurons such as IL-10 receptor [40, 69, 70]. In addition to the change of spine morphology, we found a significant alteration of neuronal activity in primary neurons with hiMGLs as measured by the calcium indicator (Fig. 6F). In fact, recent studies have demonstrated a reciprocal relationship between microglia and neurons in vivo [66]. It appears that hiMGLs can tune neuronal activity appropriately as primary microglia do. Considering the important role of microglia on synaptogenesis, these results strongly suggest that this co-culture system will prove useful for studying the interactions between neurons and microglia and investigate the pathophysiological mechanisms involving microglia in various neurodegenerative diseases.

The hiMGLs in this study will apply to several neural disease models in the future. While disease conditions,



such as AD, would disrupt and dysregulate the defensive function of microglia [52], what intrigued most scientists' interests was that multiple genes that were specifically expressed in microglia have been identified as pathogenic clues or risk genes in various neurodegenerative diseases, especially *TREM2* in AD [71–73]. Recently, by the beneficial usage of novel methodologies such as transcriptome analysis by single-cell RNA sequencing and high-resolution imaging technology, an understanding of the physiologic function of subpopulations of microglia, as well as microglia in neurodegenerative diseases has tremendously progressed [43, 74, 75]. Here, we demonstrated that the inflammasome could be formed in microglia in response to LPS and A $\beta$  peptide co-stimulation. As previously reported, the inflammasome is involved in amyloid and tau pathology in the brain of AD patients [49]. Coincidentally, although there has been a great deal of studies about *TREM2* in AD, the pathogenic mechanism is still unclear.

Overall, our newly developed method for deriving human microglia cells can potentially be applied to transplantation into brain organoids or animal brains to create more relevant experimental models for disease research or for studying the physiology of microglia. Through transcriptome analysis, we also detected that HLA-A was expressed by both CK-hiMGLs and PU-hiMGLs (Supplementary Table 4). Since hiMGLs might have the potential of transplantation for the treatment of various diseases, we think that it is crucial to analyze the expression pattern of other HLA genes in the future [76]. This technology would accelerate the research to recapitulate the in vivo signatures of human microglia.

## Conclusions

By enforcing the expression of a single critical transcription factor, PU.1, we developed a novel method for generating a large number of microglia from hiPSCs in a short period. The resulting hiPSC-derived microglia exhibited normal microglial functions such as phagocytosis and inflammatory responses. This newly developed protocol will pave the way for further studies of human microglia in both physiological and disease conditions.

## Abbreviations

hiPSCs: Induced pluripotent stem cells; hiMGLs: Microglia induced from hiPSCs; hiHPCs: Hematopoietic progenitor cells induced from hiPSCs; CK protocol: Protocol used to generate hiMGLs by multiple cytokines; PU protocol: Protocol used to generate hiMGLs by forcing the overexpression of *SPI1* as well as application of multiple cytokines; DOX: Doxycycline; OPCs: Oligodendrocyte progenitor cells; SVZ: Subventricular zone; CHIR: CHIR99021; SB: SB431542; PDL: Poly-D-lysine; OPN: Osteopontin; NHD: Nasu-Hakola disease; A $\beta$ : Amyloid beta; CCD: Cytochalasin D; LPS: Lipopolysaccharide; ASD: Autism spectrum disorder; AD: Alzheimer's disease; FTD: Frontotemporal dementia; PD: Parkinson's disease; HD: Huntington's disease

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s41232-022-00201-1>.

**Additional file 1: Fig. S1.** BMP4 signaling is crucial for hematopoietic stem cells development. (A) Schematic diagram of mesoderm development in vivo. (B) Immunostaining confirmed that both BMP4 and Wnt signaling were necessary for mesoderm formation in the first two days during differentiation. (C) Images indicating that either VEGF, activating or inhibiting TGF- $\beta$ 1 signaling could stimulate mesoderm formation. (D) The expression level of mesoderm markers was tested by qRT-PCR, confirming neither Activin A nor VEGF would enhance mesoderm formation, while Activin A might be able to inhibit the formation of paraxial mesoderm, opposite to posterior mesoderm. **Fig. S2.** Appropriate inhibition of Wnt signaling is crucial for primitive hematopoietic progenitor cell development. \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ . All data are expressed as mean  $\pm$  SEM ( $n = 3$  independent clones with  $n=3$  independent experiments). **Fig. S3.** *SPI1* expression levels in CK- and PU-protocols. (A) *SPI1* and *IRF8* expression patterns in CK-protocol from day 6 to day 18 were quantified by qRT-PCR ( $n = 3$  independent experiments). (B) *SPI1* was upregulated in other iPSC lines (201B7 and WD39) on day 7 in PU-protocol. This increase was confirmed by the expression level of the congruent transcript  $\beta$ Geo, while the 3'UTR of *SPI1*, which is not included in *SPI1* expression plasmid, was not changed, indicating that the increased *SPI1* was of exogenous origin. **Fig. S4.** Representative images during hiMGLs differentiation. Bubble-like structure that formed in the later stage of the PU-protocol (A) was not observed in the CK-protocol (B). In the last image, scale bar = 75  $\mu$ m, scale bar = 200  $\mu$ m otherwise. **Fig. S5.** The PU-protocol can induce more myeloid cells. The ratios of HPCs that are positive for myeloid cell markers, MHCII and F4/80, were determined by flow cytometry. On day 16, the MHCII+/F4/80+ cell population was increased by more than 25% in the PU-protocol (A) compared with the CK-protocol (B). Color curves in histogram indicated isotype control. **Fig. S6.** PU-protocol has a stronger ability to induce cells to the primitive hematopoietic lineage. (Related to Fig. 3 and **Supplementary Fig. 5**) Ratios of positive cells of hematopoietic progenitor cell markers (A, B: CD43 and CD34) and myeloid cell markers (C, D: CD11b and CD45) were analyzed by flow cytometry. The ratio was not changed significantly between PU-protocol (A, C) and CK-protocol (B, D). Color curves in histogram indicated isotype control. **Fig. S7.** Purity of hiMGLs analyzed by flow cytometry. After re-plated on culture dishes for one week, hiMGLs were stained with microglia-specific markers or myeloid cell markers, then analyzed by flow cytometry. A human monocyte cell line, THP-1 cells, was used as a comparative cell population to confirm the potency of antibodies. Color curves in histogram indicated isotype control. (A) The myeloid lineage marker CD45 was equally expressed in hiMGLs and THP-1. (B–F) Microglia specific markers, IBA1 (B), CD11b (C), P2RY12 (D), TMEM119 (E), and CX3CR1 (F) were expressed by all hiMGLs cells, while only a small population of THP-1 cells expressed them. (G) The major transcription factor of microglia, PU.1, was expressed by most hiMGLs cells, while almost none THP-1 cells expressed PU.1. (H, I) The AD risk gene products, DAP12 and *TREM2*, were expressed by most hiMGLs, while few THP-1 cells were positive for both proteins. **Fig. S8.** Gene expression level modestly varied between CK- and PU-protocol. (A) Heatmap showing the top 20 genes that were upregulated by PU.1 overexpression. (B) GO term enrichment analysis indicated that the genes upregulated by PU.1 overexpression were mostly related to pathogen response. (C) Heatmap showing the top 20 genes that were downregulated by PU.1 overexpression. (D) GO term enrichment analysis indicated that genes downregulated by PU.1 overexpression were mostly related to inflammation. Together with (B), the transcriptome profile showed that PU.1 overexpression would not alter the characteristics of microglia in the central nervous system. **Fig. S9.** hiMGLs were able to form the inflammasome in response to LPS or A $\beta$  peptide stimulation. Immunostaining images demonstrated that IL-1 $\beta$  expression was induced by LPS treatment, but not A $\beta$  peptide. Scale bar = 20  $\mu$ m. **Fig. S10.** A $\beta$  peptide, but not LPS alone, was able to stimulate the formation of inflammasome. (Related to Fig. 5D, **Supplementary Fig. 9**) Although LPS alone was able to stimulate the expression of IL-1 $\beta$ , inflammasome formation was not stimulated by LPS alone. While LPS treatment followed by incubation together with A $\beta$  peptide has induced

the expression of NLRP3 and ASC, A $\beta$  peptide alone was also able to up-regulate the expression of NLRP3 and ASC, despite weaker expression without pre-treatment of LPS. Scale bar = 100  $\mu$ m. **Fig. S11.** No significant differences in dendritic spines were detected between primary neurons from mouse cerebellum co-cultured with hiMGLs or in monoculture. (A) hiMGLs showed a more ramified morphology after co-culture with cerebellar neurons. Scale bar = 5  $\mu$ m. (B) Primary granule neurons were transfected with  $\beta$ -actin-GFP plasmid. This morphological difference was not observed with or without hiMGL co-culture. Scale bar = 30  $\mu$ m. (C) There was no significant difference in the number of spines between the single culture and the co-culture system. (n = 8 in single culture, 27 in co-culture; 3 independent experiments). ns, not significant. All data are expressed as mean  $\pm$  SEM. (D) Spines were counted according to different morphological groups. No significant differences were detected.

**Additional file 2: Supplementary Table S1.**

**Additional file 3: Supplementary Table S2.**

**Additional file 4: Supplementary Table S3.**

**Additional file 5: Supplementary Table S4.**

### Acknowledgements

We would like to thank Drs. Shinya Yamanaka (Kyoto University), Minoru S.H. Ko and Yuhki Nakatake (Keio University), and Haruhiko Bito (University of Tokyo) for the kind gifts of the 201B7 iPSC line, the plasmid expressing *SPI1* (PB-tet-PHS-SPI1, Id: 91215), and the plasmid expressing  $\beta$ -actin-GFP, respectively. We also thank Drs. Komei Fukushima, Hiroshi Kokubu (K Pharma, Inc.), Mitsuuru Ishikawa, Kent Imaizumi, Seiji Ishii, and Chika Saegusa (Keio University) for their kind support and technical advice and all members of the H.O. Laboratory for their generous support for this study.

### Authors' contributions

I.S., S.M., and H.W. conceived the study and planned the analysis. I.K. performed the procedures of most experiments. F.O. contributed to the establishment of the hiMGL generation protocol. S.Y. and I.S. performed the RNA-Seq library construction and data analysis. H.W. supplied the primary culture of mouse neurons. I.S., S.M., H.W., and H.O. wrote the manuscripts and prepared the figures with input of all authors. The authors read and approved the final manuscript.

### Funding

This work was supported by the funding from JSPS KAKENHI Grant Number JP21J12528 to I.S., JP20H00485 and JP21H05273 to H.O., the Research Project for Practical Applications of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED) (grant no. 15bk0104027h0003, 16bk0104016h0004, and 17bk0104016h0005 to H.O.), and the Research Center Network for Realization Research Centers/Projects of Regenerative Medicine (the Program for Intractable Disease Research Utilizing Disease-specific iPSC Cells and the Acceleration Program for Intractable Diseases Research Utilizing Disease-specific iPSC Cells) from AMED (grant no. JP15bm0609003, JP16bm0609003, JP17bm0804003, JP18bm0804003, JP19bm0804003, JP20bm0804003, and JP21bm0804003 to H.O.).

### Availability of data and materials

RNA sequencing data have been deposited in the Gene Expression Omnibus of NCBI (<https://www.ncbi.nlm.nih.gov/geo/>) under accession no. GSE178284.

### Declarations

#### Consent for publications

No applicable.

#### Ethics approval and consent to participate

Human ethics approval was obtained from the Ethics Committee of Keio University School of Medicine (Approval Number: 20080016).

#### Competing interests

The Program for Initiative Research Projects from Keio University to H.O. F.O. is employed by K Pharma, Inc., and H.O. received research funding from K Pharma, Inc. The other authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan. <sup>2</sup>Research Fellow of Japan Society for the Promotion of Science (JSPS), Tokyo 102-0083, Japan. <sup>3</sup>K Pharma, Inc., Fujisawa, Kanagawa 251-8555, Japan. <sup>4</sup>Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

Received: 31 December 2021 Accepted: 22 February 2022

Published online: 01 July 2022

### References

- Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. *Nat Rev Immunol*. 2018;18(4):225–42. <https://doi.org/10.1038/nri.2017.125>.
- Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science*. 2005;308(5726):1314–8. <https://doi.org/10.1126/science.1110647>.
- Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, et al. ATP mediates rapid microglial response to local brain injury in vivo. *Nat Neurosci*. 2005;8(6):752–8. <https://doi.org/10.1038/nn1472>.
- Frost JL, Schafer DP. Microglia: architects of the developing nervous system. *Trends Cell Biol*. 2016;26(8):587–97. <https://doi.org/10.1016/j.tcb.2016.02.006>.
- Wallace J, Lord J, Dissing-Olesen L, Stevens B, Murthy VN. Microglial depletion disrupts normal functional development of adult-born neurons in the olfactory bulb. *Elife*. 2020;9 <https://doi.org/10.7554/eLife.50531>.
- Hughes AN, Appel B. Microglia phagocytose myelin sheaths to modify developmental myelination. *Nat Neurosci*. 2020;23(9):1055–66. <https://doi.org/10.1038/s41593-020-0654-2>.
- Shigemoto-Mogami Y, Hoshikawa K, Goldman JE, Sekino Y, Sato K. Microglia enhance neurogenesis and oligodendrogenesis in the early postnatal subventricular zone. *J Neurosci*. 2014;34(6):2231–43. <https://doi.org/10.1523/JNEUROSCI.1619-13.2014>.
- Hagemeyer N, Hanft KM, Akriditou MA, Unger N, Park ES, Stanley ER, et al. Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood. *Acta Neuropathol*. 2017;134(3):441–58. <https://doi.org/10.1007/s00401-017-1747-1>.
- Ribeiro Xavier AL, Kress BT, Goldman SA, Lacerda de Menezes JR, Nedergaard M. A distinct population of microglia supports adult neurogenesis in the subventricular zone. *J Neurosci*. 2015;35(34):11848–61. <https://doi.org/10.1523/JNEUROSCI.1217-15.2015>.
- Choudhury ME, Miyaniishi K, Takeda H, Islam A, Matsuoka N, Kubo M, et al. Phagocytic elimination of synapses by microglia during sleep. *Glia*. 2020;68(1):44–59. <https://doi.org/10.1002/glia.23698>.
- Okano H, Morimoto S. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. *Cell Stem Cell*. 2022;29(2):189–208. <https://doi.org/10.1016/j.stem.2022.01.007>.
- Geirsdottir L, David E, Keren-Shaul H, Weiner A, Bohlen SC, Neuber J, et al. Cross-species single-cell analysis reveals divergence of the primate microglia program. *Cell*. 2019;179:1609–1622.e16.
- Timmerman R, Burm SM, Bajramovic JJ. An overview of. *Front Cell Neurosci*. 2018;12:242. <https://doi.org/10.3389/fncel.2018.00242>.
- Muffat J, Li Y, Yuan B, Mitalipova M, Omer A, Corcoran S, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. *Nat Med*. 2016;22(11):1358–67. <https://doi.org/10.1038/nm.4189>.
- Pandya H, Shen MJ, Ichikawa DM, Sedlock AB, Choi Y, Johnson KR, et al. Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. *Nat Neurosci*. 2017;20(5):753–9. <https://doi.org/10.1038/nn.4534>.
- Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, et al. iPSC-derived human microglia-like cells to study neurological diseases. *Neuron*. 2017;94:278–293.e9.
- Takata K, Kozaki T, Lee CZW, Thion MS, Otsuka M, Lim S, et al. Induced-pluripotent-stem-cell-derived primitive macrophages provide a platform for modeling tissue-resident macrophage differentiation and function. *Immunity*. 2017;47:183–198.e6.
- Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science*. 2010;330(6005):841–5. <https://doi.org/10.1126/science.1194637>.
- Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under

- homeostasis. *Immunity*. 2013;38(1):79–91. <https://doi.org/10.1016/j.immuni.2012.12.001>.
20. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science*. 2012;336(6077):86–90. <https://doi.org/10.1126/science.1219179>.
  21. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. *Nat Neurosci*. 2013;16(3):273–80. <https://doi.org/10.1038/nn.3318>.
  22. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007;131(5):861–72. <https://doi.org/10.1016/j.cell.2007.11.019>.
  23. Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohya M, et al. Generation of human melanocytes from induced pluripotent stem cells. *PLoS One*. 2011;6(1):e16182. <https://doi.org/10.1371/journal.pone.0016182>.
  24. Watanabe H, Smith MJ, Heilig E, Beglopoulos V, Kelleher RJ, Shen J. Indirect regulation of presenilin in CREB-mediated transcription. *J Biol Chem*. 2009;284(20):13705–13. <https://doi.org/10.1074/jbc.M809168200>.
  25. Furuya S, Makino A, Hirabayashi Y. An improved method for culturing cerebellar Purkinje cells with differentiated dendrites under a mixed monolayer setting. *Brain Res Brain Res Protoc*. 1998;3(2):192–8. [https://doi.org/10.1016/S1385-299X\(98\)00040-3](https://doi.org/10.1016/S1385-299X(98)00040-3).
  26. Furuyashiki T, Arakawa Y, Takemoto-Kimura S, Bito H, Narumiya S. Multiple spatiotemporal modes of actin reorganization by NMDA receptors and voltage-gated Ca<sup>2+</sup> channels. *Proc Natl Acad Sci U S A*. 2002;99(22):14458–63. <https://doi.org/10.1073/pnas.212148999>.
  27. Ishikawa M, Aoyama T, Shibata S, Sone T, Miyoshi H, Watanabe H, et al. miRNA-based rapid differentiation of purified neurons from hPSCs advances towards quick screening for neuronal disease phenotypes in vitro. *Cells*. 2020;9(3). <https://doi.org/10.3390/cells9030532>.
  28. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nat Biotechnol*. 2019;37(8):907–15. <https://doi.org/10.1038/s41587-019-0201-4>.
  29. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics*. 2014;30(7):923–30. <https://doi.org/10.1093/bioinformatics/btt656>.
  30. Loh KM, Chen A, Koh PW, Deng TZ, Sinha R, Tsai JM, et al. Mapping the pairwise choices leading from pluripotency to human bone, heart, and other mesoderm cell types. *Cell*. 2016;166(2):451–67. <https://doi.org/10.1016/j.cell.2016.06.011>.
  31. Moris N, Anlas K, van den Brink SC, Alemany A, Schröder J, Ghimire S, et al. An in vitro model of early anteroposterior organization during human development. *Nature*. 2020;582(7812):410–5. <https://doi.org/10.1038/s41586-020-2383-9>.
  32. Martyn I, Siggia ED, Brivanlou AH. Mapping cell migrations and fates in a gastruloid model to the human primitive streak. *Development*. 2019;146
  33. Wittler L, Shin EH, Grote P, Kispert A, Beckers A, Gossler A, et al. Expression of Msn1 in the presomitic mesoderm is controlled by synergism of Wnt signalling and Tbx6. *EMBO Rep*. 2007;8(8):784–9. <https://doi.org/10.1038/sj.embor.7401030>.
  34. Marvin MJ, Di Rocco G, Gardiner A, Bush SM, Lassar AB. Inhibition of Wnt activity induces heart formation from posterior mesoderm. *Genes Dev*. 2001;15(3):316–27. <https://doi.org/10.1101/gad.855501>.
  35. Sturgeon CM, Ditadi A, Awong G, Kennedy M, Keller G. Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells. *Nat Biotechnol*. 2014;32(6):554–61. <https://doi.org/10.1038/nbt.2915>.
  36. Mimoto MS, Kwon S, Green YS, Goldman D, Christian JL. GATA2 regulates Wnt signaling to promote primitive red blood cell fate. *Dev Biol*. 2015;407(1):1–11. <https://doi.org/10.1016/j.ydbio.2015.08.012>.
  37. Castaño J, Aranda S, Bueno C, Calero-Nieto FJ, Mejia-Ramirez E, Mosquera JL, et al. GATA2 promotes hematopoietic development and represses cardiac differentiation of human mesoderm. *Stem Cell Reports*. 2019;13(3):515–29. <https://doi.org/10.1016/j.stemcr.2019.07.009>.
  38. Yu H, Liu X, Zhong Y. The effect of osteopontin on microglia. *Biomed Res Int*. 2017;2017:1879437–6. <https://doi.org/10.1155/2017/1879437>.
  39. Huang KL, Marcora E, Pimenova AA, Di Narzo AF, Kapoor M, Jin SC, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. *Nat Neurosci*. 2017;20(8):1052–61. <https://doi.org/10.1038/nn.4587>.
  40. Ladwig A, Walter HL, Hucklenbroich J, Willuweit A, Langen KJ, Fink GR, et al. Osteopontin augments M2 microglia response and separates M1- and M2-polarized microglial activation in permanent focal cerebral ischemia. *Mediators Inflamm*. 2017;2017:7189421–11. <https://doi.org/10.1155/2017/7189421>.
  41. Yamamiya M, Tanabe S, Muramatsu R. Microglia promote the proliferation of neural precursor cells by secreting osteopontin. *Biochem Biophys Res Commun*. 2019;513(4):841–5. <https://doi.org/10.1016/j.bbrc.2019.04.076>.
  42. Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. *Nature*. 2019;566(7744):388–92. <https://doi.org/10.1038/s41586-019-0924-x>.
  43. Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. *Immunity*. 2019;50:253–271.e6.
  44. Li Q, Cheng Z, Zhou L, Darmanis S, Neff NF, Okamoto J, et al. Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. *Neuron*. 2019;101:207–223.e10.
  45. Lampron A, Larochelle A, Laflamme N, Préfontaine P, Plante MM, Sánchez MG, et al. Inefficient clearance of myelin debris by microglia impairs remyelinating processes. *J Exp Med*. 2015;212(4):481–95. <https://doi.org/10.1084/jem.20141656>.
  46. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? *Nat Med*. 2006;12(9):1005–15.
  47. Snow WM, Albenis BC. Neuronal gene targets of NF-κB and their dysregulation in Alzheimer's disease. *Front Mol Neurosci*. 2016;9:118.
  48. Zeng Q, Man R, Luo Y, Zeng L, Zhong Y, Lu B, et al. IRF-8 is involved in amyloid-β. *J Mol Neurosci*. 2017;63(2):159–64. <https://doi.org/10.1007/s12031-017-0966-1>.
  49. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. *Nature*. 2013;493(7434):674–8. <https://doi.org/10.1038/nature11729>.
  50. Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. *Nature*. 2019;575(7784):669–73. <https://doi.org/10.1038/s41586-019-1769-z>.
  51. Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease. *Nat Rev Neurosci*. 2018;19(10):610–21. <https://doi.org/10.1038/s41583-018-0055-7>.
  52. Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. *Nat Neurosci*. 2018;21(10):1359–69. <https://doi.org/10.1038/s41593-018-0242-x>.
  53. Dressman D, Elyaman W. T Cells: a growing universe of roles in neurodegenerative diseases. *Neuroscientist*. 2021;10738584211024907:10738584211024907. <https://doi.org/10.1177/10738584211024907>.
  54. Vainchtein ID, Chin G, Cho FS, Kelley KW, Miller JG, Chien EC, et al. Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. *Science*. 2018;359(6381):1269–73. <https://doi.org/10.1126/science.aal3589>.
  55. Lehrman EK, Wilton DK, Litvina EY, Welsh CA, Chang ST, Frouin A, et al. CD47 protects synapses from excess microglia-mediated pruning during development. *Neuron*. 2018;100:120–134.e6.
  56. Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, Lafaille JJ, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cell*. 2013;155(7):1596–609. <https://doi.org/10.1016/j.cell.2013.11.030>.
  57. Wang C, Yue H, Hu Z, Shen Y, Ma J, Li J, et al. Microglia mediate forgetting via complement-dependent synaptic elimination. *Science*. 2020;367(6478):688–94. <https://doi.org/10.1126/science.aaz2288>.
  58. Fattorelli N, Martinez-Muriana A, Wolfs L, Geric I, De Strooper B, Mancuso R. Stem-cell-derived human microglia transplanted into mouse brain to study human disease. *Nat Protoc*. 2021;16(2):1013–33. <https://doi.org/10.1038/s41596-020-00447-4>.
  59. Grabert K, Michoel T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP, et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. *Nat Neurosci*. 2016;19(3):504–16. <https://doi.org/10.1038/nn.4222>.
  60. Rustenhoven J, Smith AM, Smyth LC, Jansson D, Scotter EL, Swanson MEV, et al. PU.1 regulates Alzheimer's disease-associated genes in primary human microglia. *Mol Neurodegener*. 2018;13(1):44. <https://doi.org/10.1186/s13024-018-0277-1>.

61. Pimenova AA, Herbinet M, Gupta I, Machlovi SI, Bowles KR, Marcora E, et al. Alzheimer's-associated PU.1 expression levels regulate microglial inflammatory response. *Neurobiol Dis.* 2021;148:105217. <https://doi.org/10.1016/j.nbd.2020.105217>.
62. Hohaus S, Petrovick MS, Voso MT, Sun Z, Zhang DE, Tenen DG. PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. *Mol Cell Biol.* 1995;15(10):5830–45. <https://doi.org/10.1128/MCB.15.10.5830>.
63. Chen SW, Hung YS, Fuh JL, Chen NJ, Chu YS, Chen SC, et al. Efficient conversion of human induced pluripotent stem cells into microglia by defined transcription factors. *Stem Cell Reports.* 2021;16(5):1363–80. <https://doi.org/10.1016/j.stemcr.2021.03.010>.
64. Feng R, Desbordes SC, Xie H, Tillo ES, Pixley F, Stanley ER, et al. PU.1 and C/EBPalpha/beta convert fibroblasts into macrophage-like cells. *Proc Natl Acad Sci U S A.* 2008;105(16):6057–62. <https://doi.org/10.1073/pnas.0711961105>.
65. Laiosa CV, Stadtfeld M, Xie H, de Andres-Aguayo L, Graf T. Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBP alpha and PU.1 transcription factors. *Immunity.* 2006;25(5):731–44. <https://doi.org/10.1016/j.immuni.2006.09.011>.
66. Li Y, Du XF, Liu CS, Wen ZL, Du JL. Reciprocal regulation between resting microglial dynamics and neuronal activity in vivo. *Dev Cell.* 2012;23(6):1189–202. <https://doi.org/10.1016/j.devcel.2012.10.027>.
67. Zhan Y, Paolicelli RC, Sforzini F, Weinhard L, Bolasco G, Pagani F, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. *Nat Neurosci.* 2014;17(3):400–6. <https://doi.org/10.1038/nn.3641>.
68. Miyamoto A, Wake H, Ishikawa AW, Eto K, Shibata K, Murakoshi H, et al. Microglia contact induces synapse formation in developing somatosensory cortex. *Nat Commun.* 2016;7(1):12540. <https://doi.org/10.1038/ncomms12540>.
69. Lim SH, Park E, You B, Jung Y, Park AR, Park SG, et al. Neuronal synapse formation induced by microglia and interleukin 10. *PLoS One.* 2013;8(11):e81218. <https://doi.org/10.1371/journal.pone.0081218>.
70. Zhou Z, Peng X, Insolera R, Fink DJ, Mata M. IL-10 promotes neuronal survival following spinal cord injury. *Exp Neurol.* 2009;220(1):183–90. <https://doi.org/10.1016/j.expneurol.2009.08.018>.
71. Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, et al. The major risk factors for Alzheimer's disease: age, sex, and genes modulate the microglia response to A $\beta$  plaques. *Cell Rep.* 2019;27:1293–1306.e6.
72. Nott A, Holtman IR, Coufal NG, Schlachetzki JCM, Yu M, Hu R, et al. Brain cell type-specific enhancer-promoter interactome maps and disease. *Science.* 2019;366(6469):1134–9. <https://doi.org/10.1126/science.aay0793>.
73. McQuade A, Kang YJ, Hasselmann J, Jairaman A, Sotelo A, Coburn M, et al. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's disease. *Nat Commun.* 2020;11(1):5370. <https://doi.org/10.1038/s41467-020-19227-5>.
74. Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A Unique microglia type associated with restricting development of Alzheimer's disease. *Cell.* 2017;169:1276–1290.e17.
75. Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, et al. Single-cell transcriptomic analysis of Alzheimer's disease. *Nature.* 2019;570(7761):332–7. <https://doi.org/10.1038/s41586-019-1195-2>.
76. Ozaki M, Iwanami A, Nagoshi N, Kohyama J, Itakura G, Iwai H, et al. Evaluation of the immunogenicity of human iPS cell-derived neural stem/progenitor cells in vitro. *Stem Cell Res.* 2017;19:128–38. <https://doi.org/10.1016/j.scr.2017.01.007>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

